

16900 Science Drive Suites 112-114 Bowie, MD 20715 pdab.maryland.gov

February 8, 2023

The Honorable Melony G. Griffith Chair, Senate Finance Committee Miller Senate Office Building, 3 East Wing 11 Bladen Street Annapolis, Maryland 21401-1991

RE: SB202 – Prescription Drug Affordability Board - Upper Payment Limits – Letter of Support

Dear Chair Griffith:

The Maryland Prescription Drug Affordability Board writes in support of Senate Bill 202.

Ensuring that prescription drugs are accessible and affordable remains a top priority for state and federal policy makers. In 2022, six out of ten Americans reported taking prescription drugs. Yet three in ten adults reported not taking their medicines as prescribed because of cost.¹

In creating the first-in-the-nation Prescription Drug Affordability Board, Maryland led the country in devising a new approach to understanding and addressing the problem of drug affordability. This legislation will enable the Prescription Drug Affordability Board to continue its important work to make prescription drugs more affordable for Marylanders through the exploration of Upper Payment Limits.

Thank you for your consideration of this important legislation. If you have any questions, please contact Andrew York at (410) 804-0251 or andrew.york@maryland.gov.

Sincerely,

Andrew York

Executive Director

Maryland Prescription Drug Affordability Board

¹ Hamel L, Lopes L, Kirzinger A, et. al. Public Opinion on Prescription Drugs and Their Prices. Kaiser Family Foundation. October 20, 2022.

 $\frac{https://www.kff.org/health-costs/poll-finding/public-opinion-on-prescription-drugs-and-their-prices}{1/31/2023} \ Last Accessed:$